Search Results for: STAT3

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
IFNAR1 interferon alpha and beta receptor subunit 1
  • Interferon alpha/beta signaling
  • Regulation of IFNA/IFNB signaling
  • Regulation of IFNA/IFNB signaling
  • Potential therapeutics for SARS
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Evasion by RSV of host interferon responses
  • Peginterferon alfa-2a
  • Interferon alfa-n1
  • Interferon alfa-n3
  • Peginterferon alfa-2b
  • Interferon alfa-2a
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon alfacon-1
  • Interferon alfa-2b
  • Interferon alfa
  • Human interferon omega-1
  • Peginterferon beta-1a
  • Anifrolumab
  • Human interferon beta
  • Ropeginterferon alfa-2b
IFNAR2 interferon alpha and beta receptor subunit 2
  • Peginterferon alfa-2a
  • Interferon alfa-n1
  • Interferon alfa-n3
  • Peginterferon alfa-2b
  • Interferon alfa-2a
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon alfacon-1
  • Interferon alfa-2b
  • Human interferon omega-1
  • Nylidrin
  • Ropeginterferon alfa-2b
IGF1R insulin like growth factor 1 receptor
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • IRS-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Extra-nuclear estrogen signaling
  • Respiratory syncytial virus (RSV) attachment and entry
  • Insulin human
  • Insulin lispro
  • Insulin glargine
  • Insulin pork
  • Mecasermin
  • Insulin aspart
  • Insulin detemir
  • Insulin glulisine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • ATL1101
  • XL228
  • rhIGFBP-3
  • Linsitinib
  • Teprotumumab
  • (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione
  • 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE
  • Nandrolone decanoate
  • Somatrem
  • Insulin beef
  • Insulin degludec
  • Insulin argine
  • Insulin peglispro
  • Insulin tregopil
  • Dalotuzumab
  • Cixutumumab
  • Brigatinib
  • Mecasermin rinfabate
  • BMS-754807
  • KW-2450 free base
  • Synovial sarcoma
  • Malignant pleural mesothelioma
IL1RAP interleukin 1 receptor accessory protein
IL23R interleukin 23 receptor
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Crohn's disease
IL2RA interleukin 2 receptor subunit alpha
  • RAF/MAP kinase cascade
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
  • Denileukin diftitox
  • Aldesleukin
  • Basiliximab
  • Daclizumab
  • Inolimomab
  • Camidanlumab tesirine
  • Type I diabetes mellitus
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
IL2RB interleukin 2 receptor subunit beta
  • RAF/MAP kinase cascade
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
  • Denileukin diftitox
  • Aldesleukin
  • Basiliximab
  • Daclizumab
IL6R interleukin 6 receptor
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Interleukin-4 and Interleukin-13 signaling
  • Transcriptional regulation of granulopoiesis
  • Potential therapeutics for SARS
  • Tocilizumab
  • Sarilumab
  • Satralizumab
IL6ST interleukin 6 cytokine family signal transducer
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interleukin-35 Signalling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
IL7R interleukin 7 receptor
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
IMPDH2 inosine monophosphate dehydrogenase 2
  • Neutrophil degranulation
  • Purine ribonucleoside monophosphate biosynthesis
  • Potential therapeutics for SARS
  • Azathioprine ADME
  • NADH
  • Mycophenolate mofetil
  • Ribavirin
  • Mycophenolic acid
  • Mercaptopurine
  • Selenazole-4-carboxyamide-adenine dinucleotide
  • 6-Chloropurine Riboside, 5'-Monophosphate
  • Inosinic Acid
  • VX-148
IRAK1 interleukin 1 receptor associated kinase 1
  • PIP3 activates AKT signaling
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • NOD1/2 Signaling Pathway
  • p75NTR recruits signalling complexes
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • TAK1-dependent IKK and NF-kappa-B activation
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Transcriptional Regulation by MECP2
  • Interleukin-1 signaling
  • IRAK1 recruits IKK complex
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • MyD88 dependent cascade initiated on endosome
  • MyD88 cascade initiated on plasma membrane
  • Fostamatinib
JAK1 Janus kinase 1
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • ISG15 antiviral mechanism
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Other interleukin signaling
  • RAF/MAP kinase cascade
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA/IFNB signaling
  • Regulation of IFNA/IFNB signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IFNG signaling activates MAPKs
  • Evasion by RSV of host interferon responses
  • PD-L1(CD274) glycosylation and translocation to plasma membrane
  • Myricetin
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Fedratinib
  • Filgotinib
  • Abrocitinib
  • Upadacitinib
  • Pralsetinib
  • Ivarmacitinib
JAK2 Janus kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Prolactin receptor signaling
  • Prolactin receptor signaling
  • Signaling by SCF-KIT
  • Signaling by Leptin
  • RMTs methylate histone arginines
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF activation
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cyclin D associated events in G1
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • IFNG signaling activates MAPKs
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Factors involved in megakaryocyte development and platelet production
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • XL019
  • 5-phenyl-1H-indazol-3-amine
  • 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
  • 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
  • Ruxolitinib
  • Tofacitinib
  • Pacritinib
  • Baricitinib
  • Entrectinib
  • Fostamatinib
  • Fedratinib
  • Abrocitinib
  • Zanubrutinib
  • Pralsetinib
  • Polycythemia vera
JAK3 Janus kinase 3
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by ALK
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Interleukin receptor SHC signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • R-348
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Abrocitinib
  • Zanubrutinib
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
JUN Jun proto-oncogene, AP-1 transcription factor subunit
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • FCERI mediated MAPK activation
  • Activation of the AP-1 family of transcription factors
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • MAPK6/MAPK4 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Estrogen-dependent gene expression
  • WNT5:FZD7-mediated leishmania damping
  • Signaling by ALK fusions and activated point mutants
  • Regulation of PD-L1(CD274) transcription
  • Adapalene
  • Vinblastine
  • Pseudoephedrine
  • Irbesartan
  • Arsenic trioxide
  • LGD-1550
KAT5 lysine acetyltransferase 5
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • DNA Damage/Telomere Stress Induced Senescence
  • HATs acetylate histones
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Sensing of DNA Double Strand Breaks
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Estrogen-dependent gene expression
  • Defective homologous recombination repair (HRR) due to BRCA1 loss of function
  • Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
  • Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
  • Impaired BRCA2 binding to RAD51
  • Impaired BRCA2 binding to PALB2
  • Cardiogenesis
  • Coenzyme A
  • S-Acetyl-Cysteine
KDM1A lysine demethylase 1A
  • HDACs deacetylate histones
  • HDMs demethylate histones
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Regulation of PTEN gene transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • Potential therapeutics for SARS
  • Negative Regulation of CDH1 Gene Transcription
  • Factors involved in megakaryocyte development and platelet production
  • Vafidemstat
KHDRBS1 KH RNA binding domain containing, signal transduction associated 1
  • PTK6 Regulates Proteins Involved in RNA Processing
KLF15 KLF transcription factor 15
  • BMAL1:CLOCK,NPAS2 activates circadian expression

Page 5 out of 11 pages